Jozien Helleman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jozien Helleman has a total of 36 co-authors. Here are the top co-authors by number of shared publications:
- Chris H. Bangma
Erasmus MC Cancer Institute, Dept. of Urology, Rotterdam, the Netherlands
3 shared publications - Geert J. L. H. van Leenders
Department of Pathology, Erasmus MC Cancer Institute, University Medical Centre, Rotterdam, The Netherlands
3 shared publications - Monique J. Roobol
Department of Urology, Erasmus MC Cancer Institute, University Medical Centre, Rotterdam, The Netherlands
3 shared publications - Sebastiaan Remmers
Department of Urology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, 3015 Rotterdam, The Netherlands
3 shared publications - Daan Nieboer
Department of Public Health, Erasmus Medical Center, Rotterdam, the Netherlands (D.N.).
2 shared publications - Esther I. Verhoef
Department of Pathology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands
2 shared publications
Latest Publications
- Open Access
- 26 June 2021
- Published by Elsevier in Laboratory Investigation
- Vol. 34 (11) , 2064-2070
Comedonecrosis Gleason pattern 5 is associated with worse clinical outcome in operated prostate cancer patients
- 26 June 2021
- Published by Elsevier in Laboratory Investigation
- Vol. 34 (11) , 2064-2070
Open AccessComedonecrosis Gleason pattern 5 is associated with worse clinical outcome in operated prostate cancer patients
- 1 June 2021
- Published by Elsevier in European Urology
- Vol. 79, S1554-S1555
Outcomes after introducing intraoperative NeuroSAFE technique in robot-assisted radical prostatectomy
- 1 June 2021
- Published by Elsevier in European Urology
- Vol. 79, S1554-S1555
Outcomes after introducing intraoperative NeuroSAFE technique in robot-assisted radical prostatectomy
- Open Access
- 21 April 2020
- Published by Wiley in Histopathology
- Vol. 76 (5) , 755-762
Clinical outcome comparison of Grade Group 1 and Grade Group 2 prostate cancer with and without cribriform architecture at the time of radical prostatectomy
Aims: Invasive cribriform and intraductal carcinoma are associated with aggressive disease in Grade Group 2 (GG2) prostate cancer patients. However, the characteristics and clinical outcome of patients with GG2 prostate cancer without cribriform architecture (GG2−) as compared with those with Grade Group 1 (GG1) prostate cancer are unknown. The aim of this study was to investigate the clinical and pathological characteristics of GG1 and GG2− prostate cancer in radical prostatectomy specimens.Methods and results: We reviewed 835 radical prostatectomy specimens for Grade Group, pT stage, surgical margin status, and the presence of cribriform architecture. Biochemical recurrence‐free survival and metastasis were used as clinical outcomes. GG1 prostate cancer was seen in 207 patients, and GG2 prostate cancer was seen in 420 patients, of whom 228 (54%) showed cribriform architecture (GG2+) and 192 (46%) did not. GG2− patients had higher prostate‐specific antigen levels (9.4 ng/ml versus 7.0 ng/ml; P < 0.001), more often had extraprostatic extension (36% versus 11%; P < 0.001) and had more positive surgical margins (27% versus 17%; P = 0.01) than GG1 patients. GG2− patients had shorter biochemical recurrence‐free survival (hazard ratio 2.7, 95% confidence interval 1.4–4.9; P = 0.002) than GG1 patients. Lymph node and distant metastasis were observed neither in GG2− nor in GG1 patients, but occurred in 22 of 228 (10%) GG2+ patients.Conclusion: In conclusion, patients with GG2− prostate cancer at radical prostatectomy have more advanced disease and shorter biochemical recurrence‐free survival than those with GG1 prostate cancer, but both groups have a very low risk of developing metastasis.
- 21 April 2020
- Published by Wiley in Histopathology
- Vol. 76 (5) , 755-762
Open AccessClinical outcome comparison of Grade Group 1 and Grade Group 2 prostate cancer with and without cribriform architecture at the time of radical prostatectomy
Aims: Invasive cribriform and intraductal carcinoma are associated with aggressive disease in Grade Group 2 (GG2) prostate cancer patients. However, the characteristics and clinical outcome of patients with GG2 prostate cancer without cribriform architecture (GG2−) as compared with those with Grade Group 1 (GG1) prostate cancer are unknown. The aim of this study was to investigate the clinical and pathological characteristics of GG1 and GG2− prostate cancer in radical prostatectomy specimens.Methods and results: We reviewed 835 radical prostatectomy specimens for Grade Group, pT stage, surgical margin status, and the presence of cribriform architecture. Biochemical recurrence‐free survival and metastasis were used as clinical outcomes. GG1 prostate cancer was seen in 207 patients, and GG2 prostate cancer was seen in 420 patients, of whom 228 (54%) showed cribriform architecture (GG2+) and 192 (46%) did not. GG2− patients had higher prostate‐specific antigen levels (9.4 ng/ml versus 7.0 ng/ml; P < 0.001), more often had extraprostatic extension (36% versus 11%; P < 0.001) and had more positive surgical margins (27% versus 17%; P = 0.01) than GG1 patients. GG2− patients had shorter biochemical recurrence‐free survival (hazard ratio 2.7, 95% confidence interval 1.4–4.9; P = 0.002) than GG1 patients. Lymph node and distant metastasis were observed neither in GG2− nor in GG1 patients, but occurred in 22 of 228 (10%) GG2+ patients.Conclusion: In conclusion, patients with GG2− prostate cancer at radical prostatectomy have more advanced disease and shorter biochemical recurrence‐free survival than those with GG1 prostate cancer, but both groups have a very low risk of developing metastasis.
- 15 March 2019
- Published by Elsevier in European Urology Supplements
- Vol. 18 (1) , e605-e606
Discontinuation of active surveillance of men with GG2 PCa: Assessment of 14 centres in 8 countries in the Movember GAP3 consortium
- 15 March 2019
- Published by Elsevier in European Urology Supplements
- Vol. 18 (1) , e605-e606
Discontinuation of active surveillance of men with GG2 PCa: Assessment of 14 centres in 8 countries in the Movember GAP3 consortium